212061-27-3

Upstream product

• 50-00-0 formaldehyd 
• 258501-33-6 1-{5-(tert-butyl-diphenyl-silanyloxymethyl)-4-hydroxy-3-[2-(N-methyl-aminooxy)-ethoxy]-tetrahydro-furan-2-yl}-5-methyl-1H-pyrimidine-2,4-dione 
• 26879-47-0 1-(β-L-ribofuranosyl)thymine 
• 25895-60-7 sodium cyanoborohydride 
• 212061-26-2 2'-O-[(2-formadoxyiminooxy)ethyl]-5'-O-tert-butyldiphenylsilyl-5-methyluridine 
• 244277-62-1 5'-O-tert-butyldiphenylsilyl-2'-O-[(2-formadoximinooxy)ethyl]-5-methyluridine 
• 212061-25-1 5'-O-(tert-butyldiphenylsilyl)-2'-O-[2-[(2,3-dihydro-1,3-dioxo-1H-isoindol-2-yl)oxy]ethyl]-5-methyluridine 
• 212061-24-0 5'-O-(tert-butyldiphenylsilyl)-2'-O-(2-hydroxyethyl)-5-methyluridine 
• 171763-19-2 5'-O-tert-butyldiphenylsilyl-O²-2'-anhydro-5-methyluridine 
• 58479-61-1 tert-butylchlorodiphenylsilane 
• 22423-26-3 O-2,2'-cyclo-5-methyluridine 

Downstream Products

• 400821-04-7 3',5'-O-bis(tert-butyldiphenylsilyl)-2'-O-{2-[(N,N-dimethylamino)oxy]ethyl}-5-methyluridine 
• 315701-92-9 N⁴-benzoyl-2'-O-{2-[(N,N-dimethylamino)oxy]ethyl}-5-methylcytidine 
• 400821-05-8 3',5'-O-bis(tert-butyldiphenylsilyl)-2'-O-{2-[(N,N-dimethylamino)oxy]ethyl}-5-methylcytidine 
• 400821-06-9 N⁴-benzoyl-3',5'-O-bis(tert-butyldiphenylsilyl)-2'-O-{2-[(N,N-dimethylamino)oxy]ethyl}-5-methylcytidine 
• 1463-10-1 5-Methyluridine 
• 212061-29-5 5'-O-(4,4'-dimethoxytrityl)-2'-O-(2-N,N-dimethylaminooxyethyl)-5-methyluridine 

Relevant academic research and scientific papers

EFFECTS OF APOLIPOPROTEIN B INHIBITION ON GENE EXPRESSION PROFILES IN ANIMALS

Antisense compounds, compositions and methods are provided for modulating the expression of apolipoprotein B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding apolipoprotein B. Methods of using these compounds for modulation of apolipoprotein B expression and for treatment of diseases associated with expression of apolipoprotein B are provided. Methods are provided for modulating the expression of genes involved in lipid metabolism, useful in the treatment of conditions associated with cardiovascular risk. Antisense oligonucleotides targeted to apolipoprotein B reduce the level of apolipoprotein B mRNA, lower serum cholesterol and shift liver gene expression profiles from those of an obese animal towards those of a lean animal. Further provided are methods for improving the cardiovascular risk of a subject through antisense inhibition of apolipoprotein B. Also provided are methods for employing antisense oligonucleotides targeted to apolipoprotein B to modulate a cellular pathway or metabolic process.

Antisense modulation of CD40 ligand expression

Antisense compounds, compositions and methods are provided for modulating the expression of CD40 ligand. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding CD40 ligand. Methods of using these compounds for modulation of CD40 ligand expression and for treatment of diseases associated with expression of CD40 ligand are provided.

ANTISENSE MODULATION OF STEAROYL-COA DESATURASE EXPRESSION

Antisense compounds, compositions and methods are provided for modulating the expression of stearoyl-CoA desaturase. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding stearoyl-CoA desaturase. Methods of using these compounds for modulation of stearoyl-CoA desaturase expression and for treatment of diseases associated with expression of stearoyl-CoA desaturase are provided.

Antisense inhibition via RNAse H-independent reduction in mRNA

The present invention provides compositions and methods for reducing levels of a preselected mRNA, using antisense compounds targeted to a splice site or a region up to 50 nucleobases upstream of an exon/intron junction on said mRNA. Preferably, said antisense compounds do not elicit RNAse H cleavage of the mRNA.

Antisense modulation of inducible nitric oxide synthase expression

Antisense compounds, compositions and methods are provided for modulating the expression of inducible nitric oxide synthase. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding inducible nitric oxide synthase. Methods of using these compounds for modulation of inducible nitric oxide synthase expression and for treatment of diseases associated with expression of inducible nitric oxide synthase are provided.

Antisense modulation of TFAP2C expression

Antisense compounds, compositions and methods are provided for modulating the expression of TFAP2C. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding TFAP2C. Methods of using these compounds for modulation of TFAP2C expression and for treatment of diseases associated with expression of TFAP2C are provided.

Antisense modulation of p70 S6 kinase expression

Antisense compounds, compositions and methods are provided for modulating the expression of p70 S6 kinase. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding p70 S6 kinase. Methods of using these compounds for modulation of p70 S6 kinase expression and for treatment of diseases associated with expression of p70 S6 kinase are provided.

Antisense modulation of polo-like kinase expression

Antisense compounds, compositions and methods are provided for modulating the expression of polo-like kinase. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding polo-like kinase. Methods of using these compounds for modulation of polo-like kinase expression and for treatment of diseases associated with expression of polo-like kinase are provided.

Compositions and their uses directed to cell growth and maintenance proteins

Antisense compounds, compositions and methods are provided for modulating the expression of G protein-coupled receptor kinase 6. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding G p

Antisense modulation of sterol regulatory element-binding protein-1 expression

Antisense compounds, compositions and methods are provided for modulating the expression of sterol regulatory element-binding protein-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids enco